Education
About Us
Working with TipRanks
Follow Us
Icon plc (ICLR)
NASDAQ:ICLR
ICLR Stock Chart & Stats
$108.14
-$3.85(-1.73%)
At close: 4:00 PM EST
$108.14
-$3.85(-1.73%)
Day’s Range― - ―
52-Week Range$66.57 - $211.00
Previous CloseN/A
Volume330.38K
Average Volume (3M)2.57M
Market Cap
$8.26B
Enterprise Value$11.37B
Total Cash (Recent Filing)$468.89M
Total Debt (Recent Filing)$3.57B
Price to Earnings (P/E)14.6
Beta1.11
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding76,359,930
10 Day Avg. Volume1,992,753
30 Day Avg. Volume2,568,265
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)1.82
Price to Sales (P/S)2.09
P/FCF Ratio15.46
Enterprise Value/Market Cap1.38
Enterprise Value/Revenue1.40
Enterprise Value/Gross Profit5.23
Enterprise Value/Ebitda9.65
Forecast
1Y Price Target
$137.00Price Target Upside26.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)12.63
Revenue Forecast (FY)$7.98B
Bulls Say, Bears Say
Bulls Say
Client Retention And BookingsManagement indicates selective client losses have been offset by large pharmaceutical wins and confirmed renewals, while solid gross bookings suggest stabilization of market share.
Leadership TransitionExecutive succession from chief operating officer to chief executive appears smooth, with the new CEO's established relationships with major pharma clients reducing leadership-transition risk.
ValuationAnalyst notes the company's valuation is materially discounted versus peers, creating a compelling risk/reward opportunity for prospective investors.
Bears Say
Accounting InvestigationAn ongoing internal accounting investigation focused on revenue recognition poses a material risk that could uncover additional control weaknesses and undermine investor confidence.
Customer CancellationsElevated customer cancellations and wallet-share erosion are pressuring revenue and diminishing profitability prospects.
Guidance And Reporting UncertaintyWithdrawal of annual guidance and postponement of the full-year earnings release has created uncertainty around financial reporting and damaged credibility with investors.
Icon News
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $66.57 and its highest was $211.00 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $8.26B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Apr 29, 2026 which is in 57 days.
How were Icon plc’s earnings last quarter?
Currently, no data Available
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Icon plc have?
Icon plc has 76,359,930 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$137.00 (26.69% Upside)
$137.00 (26.69% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 308.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.97%
12-Months-Change
Fundamentals
Return on Equity
6.27%
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view of ICON plc's performance. While there were strong business awards and strategic investments in technology, the company faced challenges with elevated cancellations and pricing pressures affecting margins. The overall outlook remains cautiously optimistic, with expectations of normalized cancellation levels and continued technological advancements.View all ICLR earnings summariesICLR Stock 12 Month Forecast
Average Price Target
$137.00
▲(26.69% Upside)
Technical Analysis
Ownership Overview
0.40% Insiders
34.08% Mutual Funds
28.22% Other Institutional Investors
35.09% Public Companies and
Individual Investors